Delving into the Latest Updates on Nadroparin Calcium with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Nadroparine, 那曲肝素钙

+ [5]

Target-

Mechanism

Platelet aggregation inhibitors

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Venous ThrombosisAngina, UnstableThrombosis

Inactive Indication

Thromboembolism

Originator Organization

Sanofi-Synthelabo UK Ltd.

Active Organization

Lee's Pharmaceutical Holdings Ltd.Sanofi-Synthelabo UK Ltd.

Inactive Organization

GSK PlcYantai North Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

SE (24 Jun 1997),

Venous Thrombosis

Regulation-

Login to view First Approval Timeline

This project intends to conduct a multicenter, prospective, observational cohort study, aiming to explore the impact of the timing of pharmacological thromboprophylaxis initiation on postoperative bleeding risk and the effectiveness of venous thromboembolism (VTE) prevention in Chinese patients after colorectal cancer (CRC) surgery. The research outcomes of this project could provide valuable insights for optimizing the prevention and management of VTE after CRC surgery.

Start Date16 Jul 2024

Sponsor / Collaborator-

NL-OMON56793 / SuspendedNot ApplicableIIT

Safety and efficacy of nadroparin in neonates: an observational study. - SAFE-NEO

Start Date01 May 2024

Sponsor / Collaborator-

NCT06259149 / RecruitingNot ApplicableIIT

A Study of Initiation Timing of VTE Prevention After Colorectal Cancer Surgery: a Single-center, Prospective, Observational Cohort Study

This project intends to conduct a single-center, prospective, observational cohort study to explore the impact of the timing of drug prophylaxis on the risk of postoperative bleeding and the preventive effect of VTE in the prevention and management of postoperative venous thromboembolism (VTE) after colorectal cancer (CRC) surgery in Chinese population, and to determine its application and promotion value. The research results of this project can provide useful reference for optimizing the prevention and management of VTE after CRC operation.

Start Date01 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Nadroparin Calcium

Login to view more data

100 Translational Medicine associated with Nadroparin Calcium

Login to view more data

100 Patents (Medical) associated with Nadroparin Calcium

Login to view more data

810

Literatures (Medical) associated with Nadroparin Calcium

02 Apr 2024·Expert Opinion on Drug Safety

Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study

Article

Author: Yan, Ziqi ; Jiao, Zhiming ; Wang, Ganyi ; Sun, Xiaobo ; Guo, Kangyuan ; Xia, Xudong ; Feng, Da ; Feng, Zhanchun ; Zhang, Li

BACKGROUNDHemorrhage represents the most common and serious side effect of antithrombotic agents. Many studies have compared the risk of bleeding between different antithrombotic agents, but analysis of time-to-onset for hemorrhage induced by these drugs is yet sparse.METHODSWe conducted a retrospective study based on the adverse drug reaction reports on antithrombotic agents collected by the Henan Adverse Drug Reaction Monitoring Center. We assessed the reporting odds ratio to determine the disproportionate reporting signals for bleeding and the Weibull shape parameter was used to evaluate the time-to-onset data.RESULTSIn the signal detection, crude low molecular weight heparin-hemorrhage was found as a positive signal. The hemorrhage for most antithrombotic agents was random failure profiles. In particular, the hazard of hemorrhage decreased over time for warfarin and clopidogrel and increased for alteplase, nadroparin, and dipyridamole.CONCLUSIONWe found that the risk of bleeding in patients taking Crude low molecular weight heparins was significantly higher compared to other antithrombotic agents, but with a small magnificence, which may be attributed to the severely irrational use of this medication under improper management. Statistics in days, results showed that the risk of bleeding decreased over time for warfarin and clopidogrel and increased for alteplase, nadroparin, and dipyridamole.

01 Apr 2024·Thrombosis Research

Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study

Article

Author: van Onzenoort, Hein A W ; Maat, Barbara ; Mathôt, Ron A A ; van Uden, Renate C A E ; Khorsand, Nakisa ; Jaspers, Tessa C C ; Lukens, Michaël V ; Meijer, Karina ; Becker, Matthijs L ; Huls, Harmen J ; van den Bemt, Patricia M L A ; Swart, Eleonora L ; van Stralen, Karlijn J

BACKGROUNDGuidelines advise 50 % and 25 % dose reduction of the therapeutic nadroparin dose (86 IU/kg) in patients with eGFR 15-29 and 30-60 ml/min respectively. For monitoring, peak anti-Xa levels are suggested. Data lack whether this results in therapeutic anti-Xa levels or in anti-Xa levels that are comparable to those of patients without renal impairment.AIMSTo determine dose ranges in patients with renal impairment that result in therapeutic anti-Xa levels and to determine the percentage of the 86 IU/kg dose that results in anti-Xa levels normally occurring in patients without renal impairment.METHODSA retrospective cohort study was conducted in five hospitals. Patients ≥18 years of age, with an eGFR ≥ 15 ml/min were included. The first correctly sampled peak (i.e. 3-5 h after ≥ third administration, regardless of dose per patient) was included. Simulated prediction models were developed using multiple linear regression.RESULTS770 patients were included. eGFR and hospital affected the association between dose and anti-Xa level. The doses for peak anti-Xa levels of 0.75 IU/ml differed substantially between hospitals and ranged from 55 to 91, 65-359 and 68-168 IU/kg in eGFR 15-29, 30-60 and > 60 ml/min/1.73m², respectively. In eGFR 15-29 and 30-60 ml/min/1.73m², doses of 75 % and 91 % of 86 IU/kg respectively, were needed for anti-Xa levels normally occurring in patients with eGFR > 60 ml/min.CONCLUSIONWe advise against anti-Xa based dose-adjustments as long as anti-Xa assays between laboratories are not harmonized and an anti-Xa target range is not validated. A better approach might be to target levels similar to eGFR > 60 ml/min/1.73m², which are achieved by smaller dose reductions.

06 Mar 2024·The Journal of Maternal-Fetal & Neonatal MedicineQ4 · MEDICINE

Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report

Q4 · MEDICINE

Review

Author: Milanova, Milena ; Ignatov, Peter Nikolaev ; Neykova, Konstantsa Krassimirova

OBJECTIVESThe aim of our study was to investigate the interrelations of symptoms, clinical outcomes and treatment regimens in pregnant women, diagnosed with myasthenia gravis and superimposed COVID-19 infection.METHODSWe conducted an observational retrospective study between August, 2020 and July, 2021. Five patients with preexisting MG and superimposed COVID- infection were included in our study. We investigated the duration of MG, the antibody patient status, any present comorbidities, MG baseline treatment and MG severity class prior to the COVID-19 infection, MG severity class and treatment during the COVID-infection, and last but not least, the maternal and fetal clinical outcome.RESULTSNone of the participants were hospitalized as they were treated under quarantine at their homes. The most frequently reported complaints were anosmia, headache and fever, which were observed in 3 out of 5 patients. The MG severity was evaluated twice - before and after the quarantine period. Progression to a more advanced stage was found in 2 of our 5 patients. Three of the patients did not require any changes in the prescribed baseline MG treatment. In 2 patients the pyridostigmine dosage had to be increased. One patient received azithromycin and 4 patients were given LMWH (nadroparin) as specific anti-COVID measures. All patients fully recovered and gave birth to healthy newborns.CONCLUSIONTo our knowledge, this is the first study on pregnant MG patients with superimposed COVID-19 infection. Based on our observations in this study it would seem that the coexistence of MG and COVID-19 infection in pregnancy does not elicit exacerbation in neither of those conditions. Further research is needed to confirm or challenge these findings, especially with the prospects of new virus variants emerging in the future.

100 Deals associated with Nadroparin Calcium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04427	Nadroparin Calcium	B01AB06	DB08813

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Venous Thrombosis	SE	Sanofi-Synthelabo UK Ltd.	24 Jun 1997
Angina, Unstable	-	-	-
Thrombosis	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Venous Thrombosis	Preclinical	NL	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	DE	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	IT	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	HU	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	CA	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	PL	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	BE	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	RU	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	SI	GSK Plc	01 May 2006
Venous Thrombosis	Preclinical	FR	GSK Plc	01 May 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2022	Not Applicable	-	-	Main group (modified nadroparin regimen)	wnxvartsgd(snejnxfeks) = pbphqlqqfk mujmangbkx (twtcxjpdnh )	Positive	02 Jun 2022
				Control group (standard nadroparin regimen)	wnxvartsgd(snejnxfeks) = maenimtlpc mujmangbkx (twtcxjpdnh ) View more
ISTH2021	Not Applicable	COVID-19 acute kidney injury	108	nadroparin	(yqyknkhbdd) = gfckhnmadi refywqcvsk (hvqbgmsazc, 0.04% - 8.9%) View more	-	17 Jul 2021
				nadroparin	qcwpcbqvvd(lhhpyznbsr) = jzggqyzjbx ltbgelakfk (gepanjdbvh )
ISTH2020	Not Applicable	anticardiolipin - \| anti-annexin V - \| anti-b2-GPI - ... View more	146	Nadroparin Calcium	vpbdilspya(yhyilqzrok) = acxyqandsi rqagyftfka (lkmaiqqfpo ) View more	-	12 Jul 2020
NCT00881088 (PROTECT, Pubmed \| Injury)	Phase 2/3	-	467	Nadroparin	sbpvzgowop(bubacdpfha) = uixuvtqofg bmsrpakyvc (hvknmcvxns, 1.2 - 23.6)	Positive	01 Apr 2017
				Fondaparinux	sbpvzgowop(bubacdpfha) = gdbjlfewxu bmsrpakyvc (hvknmcvxns, 1.4 - 80.7)
NVALT-8 (ASCO2016)	Phase 3	Non-Small Cell Lung Cancer Adjuvant	202	Nadroparin	(fipfuggoxh) = awjdzmsjrk xrdszgwnbw (grfabuaylr )	Positive	20 May 2016
				low-molecular weight heparin (Control)	(fipfuggoxh) = xmjxizhqvs xrdszgwnbw (grfabuaylr )
NCT00951574 (Pubmed \| Lancet Oncol)	Phase 3	Metastatic Solid Tumor	1,150	Nadroparin	(qfsykvpgjc) = kyvetkteaf bnfdjlcjnf (mmzfusytrr ) View more	Positive	01 Oct 2009
				Placebo	(qfsykvpgjc) = jocbndzblm bnfdjlcjnf (mmzfusytrr ) View more
AAAAI2003	Not Applicable	Dermatophytid Reaction lymphocyte transformation test (LTT) \| nadroparin-activated basophils (BAT)	-	Nadroparin	wgqorwfrzf(zmhsxubzec) = can induce immunologically mediated adverse effects, especially thrombocytopenia, but also cutaneous reactions, as demonstrated in our case pzmnqpylwv (auiyfscyzn ) View more	Positive	07 Mar 2003